A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancer

SpringerPlus

Table 3 Tumor and response characteristics

Patient	ER 1°	PR 1°	ER met	PR met	GR^a	AR^a	Best Response	# of cycles	Reason for discontinuation
1-P	n/a	n/a	−	−	+	−	PR	6	Neuropathy
2-M	+	+	−	−	−	wk+	PD	2	PD
3-P	+	+	n/a	n/a	−	−	PD	2	PD
4-M	+	+	−	−	+	wk+	CR	4	Neutropenia
5-M	−	−	−	−	+	−	PR	10	Neuropathy
6-M	+	−	−	−	+	−	SD^b	4	PD
7-P	−	−	−	−	+	−	CR	9	PD
8-P	−	−	−	−	−	+	PR	5	Neuropathy
9-M	+	+	−	−	wk+	+	PD	2	PD

P denotes patients randomized to placebo for cycle 1 with cross over to mifepristone for cycle 2
M denotes patients randomized to mifepristone for cycle 1
ER estrogen receptor, PR progesterone, receptor, AR androgen receptor, GR glucocorticoid receptor, 1° primary, met metastatic, wk weak, n/a not available
^aPerformed on both primary and metastatic tumor (when available) and were concordant
^bRadiographically unconfirmed